NasdaqGS:TNXPBiotechs
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns
Tonix Pharmaceuticals Holding came into this earnings print with a choppy recent run, roughly flat over the past week and down about 11% over three months. The stock slipped about 2% today, yet the headline from the quarter is not the share price. The key story is the revenue ramp from its fibromyalgia franchise, with Q2 revenue of about US$13.5 million driven largely by TONMYA sales and paired with a sizeable net loss of roughly US$40.6 million.
Interested in Tonix Pharmaceuticals Holding's...